| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | -0.073 | 0.05 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.066 | 0.05 |
| mRNA | AUY922 | GDSC1000 | pan-cancer | AAC | -0.066 | 0.05 |
| mRNA | Mitomycin-C | GDSC1000 | pan-cancer | AAC | -0.066 | 0.05 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | -0.063 | 0.05 |
| mRNA | OSI-027 | GDSC1000 | pan-cancer | AAC | 0.058 | 0.05 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.072 | 0.05 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | -0.07 | 0.05 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | 0.063 | 0.06 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.06 |